A noninferiority design for a delayed calcineurin inhibitor substitution trial in kidney transplantation. Issue 4 (6th October 2020)

• Record Type: Journal Article
• Authors: Nickerson, Peter W.; Balshaw, Robert; Wiebe, Chris; Ho, Julie; Gibson, Ian W.; Bridges, Nancy D.; Rush, David N.; Heeger, Peter S.
• Is Part Of: American journal of transplantation. Volume 21:Issue 4(2021)
• Page Start: 1503
• Page End: 1512
• Publication Date: 2020-10-06
• Subjects: clinical research / practice -- clinical trial design -- immunosuppressant ‐ calcineurin inhibitor (CNI) -- immunosuppression / immune modulation -- kidney transplantation / nephrology -- rejection: acute; Transplantation of organs, tissues, etc -- Periodicals; 617.95
• DOI: 10.1111/ajt.16311
• Languages: English
• ISSNs: 1600-6135

Abstract

Abstract : Improving long‐term kidney transplant outcomes requires novel treatment strategies, including delayed calcineurin inhibitor (CNI) substitution, tested using informative trial designs. An alternative approach to the usual superiority‐based trial is a noninferiority trial design that tests whether an investigational agent is not unacceptably worse than standard of care. An informative noninferiority design, with biopsy‐proven acute rejection (BPAR) as the endpoint, requires determination of a prespecified, evidence‐based noninferiority margin for BPAR. No such information is available for delayed CNI substitution in kidney transplantation. Herein we analyzed data from recent kidney transplant trials of CNI withdrawal and "real world" CNI‐ based standard of care, containing subjects with well‐documented evidence of immune quiescence at 6 months posttransplant—ideal candidates for delayed CNI substitution. Our analysis indicates an evidence‐based noninferiority margin of 13.8% for the United States Food and Drug Administration's composite definition of BPAR between 6 and 24 months posttransplant. Sample size estimation determined that ~225 randomized subjects would be required to evaluate noninferiority for this primary clinical efficacy endpoint, and superiority for a renal function safety endpoint. Our findings provide the basis for future delayed CNI substitution noninferiority trials, thereby increasing the likelihood they will provide clinically implementable results and achieve regulatory approval. Abstract : This meta‐analysis defines a noninferiority margin to use in the design of a phase II/III delayed calcineurin inhibitor substitution trial in kidney transplantation.